MetabolicEmerging Evidence

Retatrutide

Also known as: Triple agonist, GIP/GLP-1/Glucagon agonist

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.

Benefits

6

Conditions

4

Evidence

Phase 2 trials published in NEJM 2023+ studies

Source

Synthetic triple receptor agonist

Overview

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.

Mechanism of Action

Tri-agonist activating GIP, GLP-1, and glucagon receptors simultaneously, enhances insulin secretion and suppresses appetite (GIP/GLP-1), increases energy expenditure and fat oxidation (glucagon), synergistic metabolic optimization across multiple pathways.

Key Benefits

  • ✓Exceptional weight loss (24-27% in trials)
  • ✓Increased energy expenditure
  • ✓Enhanced fat oxidation
  • ✓Appetite suppression
  • ✓Improved glycemic control
  • ✓Metabolic optimization

Clinical Applications

Obesity (investigational)Type 2 diabetes (investigational)Metabolic syndromeWeight management

Dosing Guidelines

Subcutaneous injection

Typical DosePhase 2 trials: 0.5-12 mg
FrequencyOnce weekly
DurationUnder investigation

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Research & Evidence

Evidence Level
Emerging
Studies

Phase 2 trials published in NEJM 2023

Summary

Phase 2 trial showed 24% weight loss at 48 weeks (12 mg dose), superior to any approved agent. Excellent tolerability profile. Phase 3 trials ongoing. Represents next frontier in metabolic pharmacotherapy.

Safety Information

Potential Side Effects

  • •Nausea (dose-dependent)
  • •Diarrhea
  • •Vomiting
  • •Constipation
  • •Generally well-tolerated in trials

Contraindications

  • Under investigation
  • Likely similar to GLP-1 agonists

Interactions

  • ⚠Under investigation

Quick Facts

CategoryMetabolic
SourceSynthetic triple receptor agonist
Legal StatusInvestigational, Phase 3 trials ongoing
Gabriel Brain Score
95/ 100

Source Your Protocol

Our preferred peptide partner offers lab-tested, COA-verified peptides with optional physician oversight. Sourced from US-regulated facilities.

Related Peptides

Tirzepatide

Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.

StrongLearn more →

Semaglutide

Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.

StrongLearn more →

Survodutide

Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

EmergingLearn more →